Key molecules in the differentiation and commitment program of T helper 17 (Th17) cells up-to-date

Immunology Letters

Volumn 148, Issue 2, 2012, Pages 97-109

  Hemdan, Nasr Y A ^a,b   Birkenmeier, Gerd ^a   Wichmann, Gunnar ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

^b Alexandria University Faculty Of Science   (Egypt)

Author keywords

CD4+ Th17 cytokines; Regulatory T cells; T cell differentiation; Transcription factors

Indexed keywords

AROMATIC HYDROCARBON RECEPTOR; B CELL ACTIVATING FACTOR; CYCLIC AMP RESPONSIVE ELEMENT MODULATOR; CYCLIC AMP RESPONSIVE ELEMENT MODULATOR ALPHA; EOMESODERMIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDOLEAMINE 2,3 DIOXYGENASE; INDUCIBLE T CELL COSTIMULATOR LIGAND; INTERFERON REGULATORY FACTOR 4; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 23; INTERLEUKIN 23 RECEPTOR; INTERLEUKIN 27; INTERLEUKIN 6; KYNURENIC ACID; LIVER X RECEPTOR; MAMMALIAN TARGET OF RAPAMYCIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; RECOMBINANT TRANSFORMING GROWTH FACTOR BETA; RETINOIC ACID; RETINOID RELATED ORPHAN RECEPTOR ALPHA; RETINOID RELATED ORPHAN RECEPTOR GAMMA; STAT3 PROTEIN; TRANSCRIPTION FACTOR 7; TRANSCRIPTION FACTOR FOXP3; TRANSCRIPTION FACTOR RUNX1; UNCLASSIFIED DRUG;

AUTOIMMUNE DISEASE; CELL FATE; CELL MATURATION; CELL SURVIVAL; CELLULAR PARAMETERS; CHRONIC INFLAMMATION; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; HUMAN; INTRACELLULAR SIGNALING; LYMPHOCYTE DIFFERENTIATION; MOLECULAR DYNAMICS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION; REGULATORY T LYMPHOCYTE; REVIEW; T LYMPHOCYTE PLASTICITY; TH17 CELL; UPREGULATION;

ANIMALS; AUTOIMMUNE DISEASES; AUTOIMMUNITY; CELL DIFFERENTIATION; CYTOKINES; HUMANS; INTERLEUKIN-17; MICE; NEOPLASMS; SIGNAL TRANSDUCTION; TH17 CELLS; TOR SERINE-THREONINE KINASES; TRANSCRIPTION FACTORS;

EID: 84869782318     PISSN: 01652478     EISSN: 18790542     Source Type: Journal    
DOI: 10.1016/j.imlet.2012.09.007     Document Type: Review

References (219)

1. Mosmann T.R., Coffman R.L. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol 1989, 7:145-173.
2. Josefowicz S.Z., Rudensky A. Control of regulatory T cell lineage commitment and maintenance. Immunity 2009, 30:616-625.
3. + regulatory T cells: more of the same or a division of labor?. Immunity 2009, 30:626-635.
4. Issazadeh-Navikas S., Teimer R., Bockermann R. Influence of dietary components on regulatory T cells. Mol Med 2012, 18:95-110.
5. Maggi L., Santarlasci V., Capone M., Peired A., Frosali F., Crome S.Q., et al. CD161 is a marker of all human IL-17-producing T-cell subsets and is induced by RORC. Eur J Immunol 2010, 40:2174-2181.
6. Aarvak T., Chabaud M., Miossec P., Natvig J.B. IL-17 is produced by some proinflammatory Th1/Th0 cells but not by Th2 cells. J Immunol 1999, 162:1246-1251.
7. McGeachy M.J., Bak-Jensen K.S., Chen Y., Tato C.M., Blumenschein W., McClanahan T., et al. TGF-β and IL-6 drive the production of IL-17 and IL-10 by T cells and restrain TH-17 cell-mediated pathology. Nat Immunol 2007, 8:1390-1397.
8. Shi G., Lovaas J.D., Tan C., Vistica B.P., Wawrousek E.F., Aziz M.K., et al. Cell-cell interaction with APC, not IL-23, is required for naive CD4 cells to acquire pathogenicity during Th17 lineage commitment. J Immunol 2012, 189:1220-1227.
9. Domingues H.S., Mues M., Lassmann H., Wekerle H., Krishnamoorthy G. Functional and pathogenic differences of Th1 and Th17 cells in experimental autoimmune encephalomyelitis. PLoS ONE 2010, 5:e15531.
10. Hirota K., Duarte J.H., Veldhoen M., Hornsby E., Li Y., Cua D.J., et al. Fate mapping of IL-17-producing T cells in inflammatory responses. Nat Immunol 2011, 12:255-263.
11. + Th17 cells. J Exp Med 2012, 209:1595-1609.
12. Hemdan N.Y., Birkenmeier G., Wichmann G., Abu El-Saad A.M., Krieger T., Conrad K., et al. Interleukin-17-producing T helper cells in autoimmunity. Autoimmun Rev 2010, 9:785-792.
13. Potzl J., Botteron C., Tausch E., Pedre X., Mueller A.M., Mannel D.N., et al. Tracing functional antigen-specific CCR6 Th17 cells after vaccination. PLoS ONE 2008, 3:e2951.
14. Zhang X., Gao L., Lei L., Zhong Y., Dube P., Berton M.T., et al. A MyD88-dependent early IL-17 production protects mice against airway infection with the obligate intracellular pathogen Chlamydia muridarum. J Immunol 2009, 183:1291-1300.
15. Geddes K., Rubino S.J., Magalhaes J.G., Streutker C., Le B.L., Cho J.H., et al. Identification of an innate T helper type 17 response to intestinal bacterial pathogens. Nat Med 2011, 17:837-844.
16. H17 cell differentiation. Nature 2009, 458:78-82.
17. Van Belle T.L., Esplugues E., Liao J., Juntti T., Flavell R.A., von Herrath M.G. Development of autoimmune diabetes in the absence of detectable IL-17A in a CD8-driven virally induced model. J Immunol 2011, 187:2915-2922.
18. Passos S.T., Silver J.S., O'Hara A.C., Sehy D., Stumhofer J.S., Hunter C.A. IL-6 promotes NK cell production of IL-17 during toxoplasmosis. J Immunol 2010, 184:1776-1783.
19. + T cells in mouse genital mucosa against HSV-2 infection. Immunol Lett 2012, 147:34-40.
20. Raffatellu M., Santos R.L., Verhoeven D.E., George M.D., Wilson R.P., Winter S.E., et al. Simian immunodeficiency virus-induced mucosal interleukin-17 deficiency promotes Salmonella dissemination from the gut. Nat Med 2008, 14:421-428.
21. Dejima T., Shibata K., Yamada H., Hara H., Iwakura Y., Naito S., et al. Protective role of naturally occurring interleukin-17A-producing γδ T cells in the lung at the early stage of systemic candidiasis in mice. Infect Immun 2011, 79:4503-4510.
22. Hueber A.J., Asquith D.L., Miller A.M., Reilly J., Kerr S., Leipe J., et al. Mast cells express IL-17A in rheumatoid arthritis synovium. J Immunol 2010, 184:3336-3340.
23. Godinez I., Raffatellu M., Chu H., Paixao T.A., Haneda T., Santos R.L., et al. Interleukin-23 orchestrates mucosal responses to Salmonella enterica serotype Typhimurium in the intestine. Infect Immun 2009, 77:387-398.
24. Ye P., Rodriguez F.H., Kanaly S., Stocking K.L., Schurr J., Schwarzenberger P., et al. Requirement of interleukin 17 receptor signaling for lung CXC chemokine and granulocyte colony-stimulating factor expression, neutrophil recruitment, and host defense. J Exp Med 2001, 194:519-527.
25. Puel A., Cypowyj S., Bustamante J., Wright J.F., Liu L., Lim H.K., et al. Chronic mucocutaneous candidiasis in humans with inborn errors of interleukin-17 immunity. Science 2011, 332:65-68.
26. Liu L., Okada S., Kong X.F., Kreins A.Y., Cypowyj S., Abhyankar A., et al. Gain-of-function human STAT1 mutations impair IL-17 immunity and underlie chronic mucocutaneous candidiasis. J Exp Med 2011, 208:1635-1648.
27. H17 and regulatory T cells in Behçet disease. J Allergy Clin Immunol 2011, 128:655-664.
28. H17 cells. Nature 2007, 448:484-487.
29. Avery D.T., Deenick E.K., Ma C.S., Suryani S., Simpson N., Chew G.Y., et al. B cell-intrinsic signaling through IL-21 receptor and STAT3 is required for establishing long-lived antibody responses in humans. J Exp Med 2010, 207:155-171.
30. Poholek A.C., Hansen K., Hernandez S.G., Eto D., Chandele A., Weinstein J.S., et al. In vivo regulation of Bcl6 and T follicular helper cell development. J Immunol 2010, 185:313-326.
31. Bansal R.R., Mackay C.R., Moser B., Eberl M. IL-21 enhances the potential of human γδ T cells to provide B-cell help. Eur J Immunol 2012, 42:110-119.
32. Costanzo A., Chimenti M.S., Botti E., Caruso R., Sarra M., Monteleone G. IL-21 in the pathogenesis and treatment of skin diseases. J Dermatol Sci 2010, 60:61-66.
33. Yi J.S., Cox M.A., Zajac A.J. Interleukin-21: a multifunctional regulator of immunity to infections. Microbes Infect 2010, 12:1111-1119.
34. H2 cells. Nat Immunol 2009, 10:864-871.
35. Eyerich S., Eyerich K., Pennino D., Carbone T., Nasorri F., Pallotta S., et al. Th22 cells represent a distinct human T cell subset involved in epidermal immunity and remodeling. J Clin Invest 2009, 119:3573-3585.
36. Munoz M., Heimesaat M.M., Danker K., Struck D., Lohmann U., Plickert R., et al. Interleukin (IL)-23 mediates Toxoplasma gondii-induced immunopathology in the gut via matrixmetalloproteinase-2 and IL-22 but independent of IL-17. J Exp Med 2009, 206:3047-3059.
37. Eyerich S., Wagener J., Wenzel V., Scarponi C., Pennino D., Albanesi C., et al. IL-22 and TNF-α represent a key cytokine combination for epidermal integrity during infection with Candida albicans. Eur J Immunol 2011, 41:1894-1901.
38. Hirota K., Ahlfors H., Duarte J.H., Stockinger B. Regulation and function of innate and adaptive interleukin-17-producing cells. EMBO Rep 2012, 13:113-120.
39. - T cells or are self-induced to become Th17 cells in the absence of exogenous TGF-β. J Immunol 2007, 178:6725-6729.
40. H17 cell differentiation by antagonizing RORγt function. Nature 2008, 453:236-240.
41. Du J., Huang C., Zhou B., Ziegler S.F. Isoform-specific inhibition of RORα-mediated transcriptional activation by human FOXP3. J Immunol 2008, 180:4785-4792.
42. + T cells in an interleukin-10-dependent manner. Immunity 2011, 34:554-565.
43. Liu B., Tonkonogy S.L., Sartor R.B. Antigen-presenting cell production of IL-10 inhibits T-helper 1 and 17 cell responses and suppresses colitis in mice. Gastroenterology 2011, 141:653-662. 662.
44. Yang X.P., Ghoreschi K., Steward-Tharp S.M., Rodriguez-Canales J., Zhu J., Grainger J.R., et al. Opposing regulation of the locus encoding IL-17 through direct, reciprocal actions of STAT3 and STAT5. Nat Immunol 2011, 12:247-254.
45. H17 phenotype and accelerates autoimmunity. J Mol Cell Biol 2012, 4:121-123.
46. + regulatory T cells promote Th17 cells in vitro and enhance host resistance in mouse Candida albicans Th17 cell infection model. Immunity 2011, 34:422-434.
47. + regulatory T cells promote T helper 17 cell development in vivo through regulation of interleukin-2. Immunity 2011, 34:409-421.
48. Mellor A.L., Munn D.H. IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat Rev Immunol 2004, 4:762-774.
49. Baban B., Chandler P.R., Sharma M.D., Pihkala J., Koni P.A., Munn D.H., et al. IDO activates regulatory T cells and blocks their conversion into Th17-like T cells. J Immunol 2009, 183:2475-2483.
50. Curti A., Trabanelli S., Onofri C., Aluigi M., Salvestrini V., Ocadlikova D., et al. Indoleamine 2,3-dioxygenase-expressing leukemic dendritic cells impair a leukemia-specific immune response by inducing potent T regulatory cells. Haematologica 2010, 95:2022-2030.
51. Chen W., Liang X., Peterson A.J., Munn D.H., Blazar B.R. The indoleamine 2,3-dioxygenase pathway is essential for human plasmacytoid dendritic cell-induced adaptive T regulatory cell generation. J Immunol 2008, 181:5396-5404.
52. + dendritic cells express indoleamine 2,3-dioxygenase which influences T regulatory/T effector cell balance and oral tolerance induction. Gut 2010, 59:595-604.
53. Smith A.W., Doonan B.P., Tyor W.R., Abou-Fayssal N., Haque A., Banik N.L. Regulation of Th1/Th17 cytokines and IDO gene expression by inhibition of calpain in PBMCs from MS patients. J Neuroimmunol 2011, 232:179-185.
54. Baban B., Chandler P.R., Johnson B.A., Huang L., Li M., Sharpe M.L., et al. Physiologic control of IDO competence in splenic dendritic cells. J Immunol 2011, 187:2329-2335.
55. Favre D., Mold J., Hunt P.W., Kanwar B., Loke P., Seu L., et al. Tryptophan catabolism by indoleamine 2,3-dioxygenase 1 alters the balance of TH17 to regulatory T cells in HIV disease. Sci Transl Med 2010, 2:32ra36.
56. + mucosal NK cells during SIV infection. Blood 2011, 118:3321-3330.
57. Mezrich J.D., Fechner J.H., Zhang X., Johnson B.P., Burlingham W.J., Bradfield C.A. An interaction between kynurenine and the aryl hydrocarbon receptor can generate regulatory T cells. J Immunol 2010, 185:3190-3198.
58. Dinatale B.C., Murray I.A., Schroeder J.C., Flaveny C.A., Lahoti T.S., Laurenzana E.M., et al. Kynurenic acid is a potent endogenous aryl hydrocarbon receptor ligand that synergistically induces interleukin-6 in the presence of inflammatory signaling. Toxicol Sci 2010, 115:89-97.
59. Mucida D., Park Y., Kim G., Turovskaya O., Scott I., Kronenberg M., et al. Reciprocal TH17 and regulatory T cell differentiation mediated by retinoic acid. Science 2007, 317:256-260.
60. Sun C.M., Hall J.A., Blank R.B., Bouladoux N., Oukka M., Mora J.R., et al. Small intestine lamina propria dendritic cells promote de novo generation of Foxp3 T reg cells via retinoic acid. J Exp Med 2007, 204:1775-1785.
61. Zhao J., Lloyd C.M., Noble A. Th17 responses in chronic allergic airway inflammation abrogate regulatory T-cell-mediated tolerance and contribute to airway remodeling. Mucosal Immunol 2012, 10.1038/mi.2012.76.
62. H17 cells. Nature 2008, 454:350-352.
63. Yoshimura A., Muto G. TGF-β function in immune suppression. Curr Top Microbiol Immunol 2011, 350:127-147.
64. Do J.S., Fink P.J., Li L., Spolski R., Robinson J., Leonard W.J., et al. Cutting edge: spontaneous development of IL-17-producing γδT cells in the thymus occurs via a TGF-β1-dependent mechanism. J Immunol 2010, 184:1675-1679.
65. Das J., Ren G., Zhang L., Roberts A.I., Zhao X., Bothwell A.L., et al. Transforming growth factor β is dispensable for the molecular orchestration of Th17 cell differentiation. J Exp Med 2009, 206:2407-2416.
66. Walsh K.P., Brady M.T., Finlay C.M., Boon L., Mills K.H. Infection with a helminth parasite attenuates autoimmunity through TGF-β-mediated suppression of Th17 and Th1 responses. J Immunol 2009, 183:1577-1586.
67. Goodman W.A., Levine A.D., Massari J.V., Sugiyama H., McCormick T.S., Cooper K.D. IL-6 Signaling in Psoriasis Prevents Immune Suppression by Regulatory T Cells. J Immunol 2009, 183:3170-3176.
68. H17 cells in the absence of TGF-β signalling. Nature 2010, 467:967-971.
69. Acosta-Rodriguez E.V., Napolitani G., Lanzavecchia A., Sallusto F. Interleukins 1β and 6 but not transforming growth factor-β are essential for the differentiation of interleukin 17-producing human T helper cells. Nat Immunol 2007, 8:942-949.
70. Sutton C., Brereton C., Keogh B., Mills K.H., Lavelle E.C. A crucial role for interleukin (IL)-1 in the induction of IL-17-producing T cells that mediate autoimmune encephalomyelitis. J Exp Med 2006, 203:1685-1691.
71. Ben-Sasson S.Z., Hu-Li J., Quiel J., Cauchetaux S., Ratner M., Shapira I., et al. IL-1 acts directly on CD4 T cells to enhance their antigen-driven expansion and differentiation. Proc Natl Acad Sci U S A 2009, 106:7119-7124.
72. Blakytny R., Ludlow A., Martin G.E., Ireland G., Lund L.R., Ferguson M.W., et al. Latent TGF-β1 activation by platelets. J Cell Physiol 2004, 199:67-76.
73. Labelle M., Begum S., Hynes R.O. Direct signaling between platelets and cancer cells induces an epithelial-mesenchymal-like transition and promotes metastasis. Cancer Cell 2011, 20:576-590.
74. + T cells. J Biol Chem 2012, 287:2943-2947.
75. Oida T., Weiner H.L. Murine CD4 T cells produce a new form of TGF-β as measured by a newly developed TGF-β bioassay. PLoS ONE 2011, 6:e18365.
76. + iNKT cells are under TGF-β control. Blood 2012, 119:3486-3494.
77. Carrier Y., Yuan J., Kuchroo V.K., Weiner H.L. Th3 cells in peripheral tolerance. I. Induction of Foxp3-positive regulatory T cells by Th3 cells derived from TGF-β T cell-transgenic mice. J Immunol 2007, 178:179-185.
78. Lee Y.K., Turner H., Maynard C.L., Oliver J.R., Chen D., Elson C.O., et al. Late developmental plasticity in the T helper 17 lineage. Immunity 2009, 30:92-107.
79. Lexberg M.H., Taubner A., Forster A., Albrecht I., Richter A., Kamradt T., et al. Th memory for interleukin-17 expression is stable in vivo. Eur J Immunol 2008, 38:2654-2664.
80. Qin H., Wang L., Feng T., Elson C.O., Niyongere S.A., Lee S.J., et al. TGF-β promotes Th17 cell development through inhibition of SOCS3. J Immunol 2009, 183:97-105.
81. Chen Z., Laurence A., Kanno Y., Pacher-Zavisin M., Zhu B.M., Tato C., et al. Selective regulatory function of Socs3 in the formation of IL-17-secreting T cells. Proc Natl Acad Sci U S A 2006, 103:8137-8142.
82. Tanaka K., Ichiyama K., Hashimoto M., Yoshida H., Takimoto T., Takaesu G., et al. Loss of suppressor of cytokine signaling 1 in helper T cells leads to defective Th17 differentiation by enhancing antagonistic effects of IFN-γ on STAT3 and Smads. J Immunol 2008, 180:3746-3756.
83. Liu Y., Islam E.A., Jarvis G.A., Gray-Owen S.D., Russell M.W. Neisseria gonorrhoeae selectively suppresses the development of Th1 and Th2 cells, and enhances Th17 cell responses, through TGF-β-dependent mechanisms. Mucosal Immunol 2012, 5:320-331.
84. Malhotra N., Robertson E., Kang J. SMAD2 is essential for TGFβ-mediated Th17 cell generation. J Biol Chem 2010, 285:29044-29048.
85. Martinez G.J., Zhang Z., Chung Y., Reynolds J.M., Lin X., Jetten A.M., et al. Smad3 differentially regulates the induction of regulatory and inflammatory T cell differentiation. J Biol Chem 2009, 284:35283-35286.
86. Martinez G.J., Zhang Z., Reynolds J.M., Tanaka S., Chung Y., Liu T., et al. Smad2 positively regulates the generation of Th17 cells. J Biol Chem 2010, 285:29039-29043.
87. Takimoto T., Wakabayashi Y., Sekiya T., Inoue N., Morita R., Ichiyama K., et al. Smad2 and Smad3 are redundantly essential for the TGF-β-mediated regulation of regulatory T plasticity and Th1 development. J Immunol 2010, 185:842-855.
88. Hahn J.N., Falck V.G., Jirik F.R. Smad4 deficiency in T cells leads to the Th17-associated development of premalignant gastroduodenal lesions in mice. J Clin Invest 2011, 121:4030-4042.
89. Ichiyama K., Sekiya T., Inoue N., Tamiya T., Kashiwagi I., Kimura A., et al. Transcription factor Smad-independent T helper 17 cell induction by transforming-growth factor-β is mediated by suppression of eomesodermin. Immunity 2011, 34:741-754.
90. H17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature 2007, 445:648-651.
91. de Wit J., Souwer Y., van Beelen A.J., de G.R., Muller F.J., Klaasse B.H., et al. CD5 costimulation induces stable Th17 development by promoting IL-23R expression and sustained STAT3 activation. Blood 2011, 118:6107-6114.
92. Lai Kwan L.Q., King Hung K.O., Zheng B.J., Lu L. Local BAFF gene silencing suppresses Th17-cell generation and ameliorates autoimmune arthritis. Proc Natl Acad Sci U S A 2008, 105:14993-14998.
93. Abdulahad W.H., Kroese F.G., Vissink A., Bootsma H. Immune regulation and B-cell depletion therapy in patients with primary Sjogren's syndrome. J Autoimmun 2012, 39:103-111.
94. H-17 cells. Nat Immunol 2009, 10:167-175.
95. Frey O., Meisel J., Hutloff A., Bonhagen K., Bruns L., Kroczek R.A., et al. Inducible costimulator (ICOS) blockade inhibits accumulation of polyfunctional T helper 1/T helper 17 cells and mitigates autoimmune arthritis. Ann Rheum Dis 2010, 69:1495-1501.
96. Li W.X., Pan H.F., Chen G.P., Tao J.H., Li X.P., Ye D.Q. Expression of inducible co-stimulator on peripheral blood T lymphocytes in patients with lupus nephritis. Rheumatol Int 2012, 32:2051-2055.
97. Apostolidis S.A., Crispin J.C., Tsokos G.C. IL-17-producing T cells in lupus nephritis. Lupus 2011, 20:120-124.
98. + regulatory T cells in islets of nonobese diabetic mice. J Immunol 2012, 188:1064-1074.
99. Chen Y., Shen S., Gorentla B.K., Gao J., Zhong X.P. Murine regulatory T cells contain hyperproliferative and death-prone subsets with differential ICOS expression. J Immunol 2012, 188:1698-1707.
100. Nie X., Cai G., Zhang W., Wang H., Wu B., Li Q., et al. Lipopolysaccharide mediated mast cells induce IL-10 producing regulatory T cells through the ICOSL/ICOS axis. Clin Immunol 2012, 142:269-279.
101. Whitehead G.S., Wilson R.H., Nakano K., Burch L.H., Nakano H., Cook D.N. IL-35 production by inducible costimulator (ICOS)-positive regulatory T cells reverses established IL-17-dependent allergic airways disease. J Allergy Clin Immunol 2012, 129:207-215.
102. Nouailles G., Day T.A., Kuhlmann S., Loewe D., Dorhoi A., Gamradt P., et al. Impact of inducible co-stimulatory molecule (ICOS) on T-cell responses and protection against Mycobacterium tuberculosis infection. Eur J Immunol 2011, 41:981-991.
103. + T cells: a critical mechanism for protection from severe immunopathology during malaria infection. J Immunol 2012, 188:1178-1190.
104. Ko H.J., Yang H., Yang J.Y., Seo S.U., Chang S.Y., Seong J.K., et al. Expansion of Tfh-like cells during chronic Salmonella exposure mediates the generation of autoimmune hypergammaglobulinemia in MyD88-deficient mice. Eur J Immunol 2012, 42:618-628.
105. + T cells and their interleukin-10 secretion to assist in hepatitis C virus clearance. J Gastroenterol Hepatol 2012, 27:823-831.
106. Hirahara K., Ghoreschi K., Laurence A., Yang X.P., Kanno Y., O'Shea J.J. Signal transduction pathways and transcriptional regulation in Th17 cell differentiation. Cytokine Growth Factor Rev 2010, 21:425-434.
107. + T helper cells. Cell 2006, 126:1121-1133.
108. Yang X.O., Pappu B.P., Nurieva R., Akimzhanov A., Kang H.S., Chung Y., et al. T helper 17 lineage differentiation is programmed by orphan nuclear receptors RORα and RORγ. Immunity 2008, 28:29-39.
109. Ichiyama K., Yoshida H., Wakabayashi Y., Chinen T., Saeki K., Nakaya M., et al. Foxp3 inhibits RORγt-mediated IL-17A mRNA transcription through direct interaction with RORγt. J Biol Chem 2008, 283:17003-17008.
110. Keerthivasan S., Suleiman R., Lawlor R., Roderick J., Bates T., Minter L., et al. Notch signaling regulates mouse and human Th17 differentiation. J Immunol 2011, 187:692-701.
111. Mukherjee S., Schaller M.A., Neupane R., Kunkel S.L., Lukacs N.W. Regulation of T cell activation by Notch ligand, DLL4, promotes IL-17 production and Rorc activation. J Immunol 2009, 182:7381-7388.
112. Stevens E.A., Mezrich J.D., Bradfield C.A. The aryl hydrocarbon receptor: a perspective on potential roles in the immune system. Immunology 2009, 127:299-311.
113. H17 cell differentiation by the aryl hydrocarbon receptor. Nature 2008, 453:65-71.
114. Ramirez J.M., Brembilla N.C., Sorg O., Chicheportiche R., Matthes T., Dayer J.M., et al. Activation of the aryl hydrocarbon receptor reveals distinct requirements for IL-22 and IL-17 production by human T helper cells. Eur J Immunol 2010, 40:2450-2459.
115. H17-cell-mediated autoimmunity to environmental toxins. Nature 2008, 453:106-109.
116. Martin B., Hirota K., Cua D.J., Stockinger B., Veldhoen M. Interleukin-17-producing γδ T cells selectively expand in response to pathogen products and environmental signals. Immunity 2009, 31:321-330.
117. Vogel C.F., Goth S.R., Dong B., Pessah I.N., Matsumura F. Aryl hydrocarbon receptor signaling mediates expression of indoleamine 2,3-dioxygenase. Biochem Biophys Res Commun 2008, 375:331-335.
118. Kimura A., Naka T., Nohara K., Fujii-Kuriyama Y., Kishimoto T. Aryl hydrocarbon receptor regulates Stat1 activation and participates in the development of Th17 cells. Proc Natl Acad Sci U S A 2008, 105:9721-9726.
119. Singh N.P., Singh U.P., Singh B., Price R.L., Nagarkatti M., Nagarkatti P.S. Activation of aryl hydrocarbon receptor (AhR) leads to reciprocal epigenetic regulation of FoxP3 and IL-17 expression and amelioration of experimental colitis. PLoS ONE 2011, 6:e23522.
120. + T-cell differentiation. Front Immunol 2012, 3:223.
121. Schindler C., Strehlow I. Cytokines and STAT signaling. Adv Pharmacol 2000, 47:113-174.
122. + T helper cell differentiation and inflammatory diseases. Cytokine 2009, 47:149-156.
123. Minegishi Y., Saito M., Tsuchiya S., Tsuge I., Takada H., Hara T., et al. Dominant-negative mutations in the DNA-binding domain of STAT3 cause hyper-IgE syndrome. Nature 2007, 448:1058-1062.
124. H17 cell differentiation in subjects with autosomal dominant hyper-IgE syndrome. Nature 2008, 452:773-776.
125. Minegishi Y., Saito M., Nagasawa M., Takada H., Hara T., Tsuchiya S., et al. Molecular explanation for the contradiction between systemic Th17 defect and localized bacterial infection in hyper-IgE syndrome. J Exp Med 2009, 206:1291-1301.
126. + T cells prevents development of experimental autoimmune diseases. J Immunol 2008, 180:6070-6076.
127. H17 responses in a Stat3-dependent manner. Science 2009, 326:986-991.
128. H2 responses. Nature 2009, 458:351-356.
129. Koch M.A., Tucker-Heard G., Perdue N.R., Killebrew J.R., Urdahl K.B., Campbell D.J. The transcription factor T-bet controls regulatory T cell homeostasis and function during type 1 inflammation. Nat Immunol 2009, 10:595-602.
130. + T cells. Proc Natl Acad Sci U S A 2008, 105:15890-15895.
131. Biswas P.S., Gupta S., Chang E., Song L., Stirzaker R.A., Liao J.K., et al. Phosphorylation of IRF4 by ROCK2 regulates IL-17 and IL-21 production and the development of autoimmunity in mice. J Clin Invest 2010, 120:3280-3295.
132. Chen Q., Yang W., Gupta S., Biswas P., Smith P., Bhagat G., et al. IRF-4-binding protein inhibits interleukin-17 and interleukin-21 production by controlling the activity of IRF-4 transcription factor. Immunity 2008, 29:899-911.
133. H-17 cells requires interferon-regulatory factor 4. Nat Immunol 2007, 8:958-966.
134. Kwon H., Thierry-Mieg D., Thierry-Mieg J., Kim H.P., Oh J., Tunyaplin C., et al. Analysis of interleukin-21-induced Prdm1 gene regulation reveals functional cooperation of STAT3 and IRF4 transcription factors. Immunity 2009, 31:941-952.
135. Staudt V., Bothur E., Klein M., Lingnau K., Reuter S., Grebe N., et al. Interferon-regulatory factor 4 is essential for the developmental program of T helper 9 cells. Immunity 2010, 33:192-202.
136. Mao Z.J., Tang Q.J., Zhang C.A., Qin Z.F., Pang B., Wei P.K., et al. Anti-proliferation and anti-invasion effects of diosgenin on gastric cancer BGC-823 cells with HIF-1α shRNAs. Int J Mol Sci 2012, 13:6521-6533.
137. Evans C.E., Branco-Price C., Johnson R.S. HIF-mediated endothelial response during cancer progression. Int J Hematol 2012, 95:471-477.
138. Harada H., Inoue M., Itasaka S., Hirota K., Morinibu A., Shinomiya K., et al. Cancer cells that survive radiation therapy acquire HIF-1 activity and translocate towards tumour blood vessels. Nat Commun 2012, 3:783.
139. reg cells. J Exp Med 2011, 208:1367-1376.
140. Hot A., Zrioual S., Lenief V., Miossec P. IL-17 and tumour necrosis factor α combination induces a HIF-1α-dependent invasive phenotype in synoviocytes. Ann Rheum Dis 2012, 71:1393-1401.
141. reg balance by hypoxia-inducible factor 1. Cell 2011, 146:772-784.
142. Westra J., Molema G., Kallenberg C.G. Hypoxia-inducible factor-1 as regulator of angiogenesis in rheumatoid arthritis - therapeutic implications. Curr Med Chem 2010, 17:254-263.
143. Semenza G.L. Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy. Trends Pharmacol Sci 2012, 33:207-214.
144. Salnikow K., Davidson T., Zhang Q., Chen L.C., Su W., Costa M. The involvement of hypoxia-inducible transcription factor-1-dependent pathway in nickel carcinogenesis. Cancer Res 2003, 63:3524-3530.
145. Martinez G.J., Dong C. BATF: bringing (in) another Th17-regulating factor. J Mol Cell Biol 2009, 1:66-68.
146. H17 differentiation. Nature 2009, 460:405-409.
147. Ise W., Kohyama M., Schraml B.U., Zhang T., Schwer B., Basu U., et al. The transcription factor BATF controls the global regulators of class-switch recombination in both B cells and T cells. Nat Immunol 2011, 12:536-543.
148. Zhang F., Meng G., Strober W. Interactions among the transcription factors Runx1, RORγt and Foxp3 regulate the differentiation of interleukin 17-producing T cells. Nat Immunol 2008, 9:1297-1306.
149. H17 differentiation by preventing Runx1-mediated activation of the gene encoding RORγt. Nat Immunol 2011, 12:96-104.
150. Powolny-Budnicka I., Riemann M., Tanzer S., Schmid R.M., Hehlgans T., Weih F. RelA and RelB transcription factors in distinct thymocyte populations control lymphotoxin-dependent interleukin-17 production in γδ T cells. Immunity 2011, 34:364-374.
151. Luo J.L., Maeda S., Hsu L.C., Yagita H., Karin M. Inhibition of NF-κB in cancer cells converts inflammation- induced tumor growth mediated by TNFα to TRAIL-mediated tumor regression. Cancer Cell 2004, 6:297-305.
152. Rius J., Guma M., Schachtrup C., Akassoglou K., Zinkernagel A.S., Nizet V., et al. NF-κB links innate immunity to the hypoxic response through transcriptional regulation of HIF-1α. Nature 2008, 453:807-811.
153. Joyce D., Albanese C., Steer J., Fu M., Bouzahzah B., Pestell R.G. NF-κB and cell-cycle regulation: the cyclin connection. Cytokine Growth Factor Rev 2001, 12:73-90.
154. Huang S., Pettaway C.A., Uehara H., Bucana C.D., Fidler I.J. Blockade of NF-κB activity in human prostate cancer cells is associated with suppression of angiogenesis, invasion, and metastasis. Oncogene 2001, 20:4188-4197.
155. Pacak K., Sirova M., Giubellino A., Lencesova L., Csaderova L., Laukova M., et al. NF-κB inhibition significantly upregulates the norepinephrine transporter system, causes apoptosis in pheochromocytoma cell lines and prevents metastasis in an animal model. Int J Cancer 2012, 131:2445-2455.
156. Umemura N., Zhu J., Mburu Y.K., Forero A., Hsieh P.N., Muthuswamy R., et al. Defective NF-κB signaling in metastatic head and neck cancer cells leads to enhanced apoptosis by double-stranded RNA. Cancer Res 2012, 72:45-55.
157. Jennewein C., Karl S., Baumann B., Micheau O., Debatin K.M., Fulda S. Identification of a novel pro-apoptotic role of NF-κB in the regulation of TRAIL- and CD95-mediated apoptosis of glioblastoma cells. Oncogene 2012, 31:1468-1474.
158. Sareddy G.R., Geeviman K., Ramulu C., Babu P.P. The nonsteroidal anti-inflammatory drug celecoxib suppresses the growth and induces apoptosis of human glioblastoma cells via the NF-κB pathway. J Neurooncol 2012, 106:99-109.
159. Chen G., Hardy K., Bunting K., Daley S., Ma L., Shannon M.F. Regulation of the IL-21 gene by the NF-κB transcription factor c-Rel. J Immunol 2010, 185:2350-2359.
160. Li L., Ruan Q., Hilliard B., DeVirgiliis J., Karin M., Chen Y.H. Transcriptional regulation of the Th17 immune response by IKKα. J Exp Med 2011, 208:787-796.
161. H17 development by cooperating with ROR nuclear receptors. Nature 2010, 464:1381-1385.
162. Ahlmann M., Varga G., Sturm K., Lippe R., Benedyk K., Viemann D., et al. The cyclic AMP response element modulator α suppresses CD86 expression and APC function. J Immunol 2009, 182:4167-4174.
163. Hedrich C.M., Rauen T., Kis-Toth K., Kyttaris V.C., Tsokos G.C. cAMP-responsive element modulator α (CREMα) suppresses IL-17F protein expression in T lymphocytes from patients with systemic lupus erythematosus (SLE). J Biol Chem 2012, 287:4715-4725.
164. Hedrich C.M., Rauen T., Tsokos G.C. cAMP-responsive element modulator (CREM)α protein signaling mediates epigenetic remodeling of the human interleukin-2 gene: implications in systemic lupus erythematosus. J Biol Chem 2011, 286:43429-43436.
165. Rauen T., Hedrich C.M., Juang Y.T., Tenbrock K., Tsokos G.C. cAMP-responsive element modulator (CREM)α protein induces interleukin 17A expression and mediates epigenetic alterations at the interleukin-17A gene locus in patients with systemic lupus erythematosus. J Biol Chem 2011, 286:43437-43446.
166. Ishizu A., Abe A., Miyatake Y., Baba T., Iinuma C., Tomaru U., et al. Cyclic AMP response element-binding protein is implicated in IL-6 production from arthritic synovial cells. Mod Rheumatol 2010, 20:134-138.
167. Cui G., Qin X., Wu L., Zhang Y., Sheng X., Yu Q., et al. Liver X receptor (LXR) mediates negative regulation of mouse and human Th17 differentiation. J Clin Invest 2011, 121:658-670.
168. + T cells depend on T cell factor 1. Immunity 2010, 33:229-240.
169. Yu Q., Sharma A., Ghosh A., Sen J.M. T cell factor-1 negatively regulates expression of IL-17 family of cytokines and protects mice from experimental autoimmune encephalomyelitis. J Immunol 2011, 186:3946-3952.
170. Ma J., Wang R., Fang X., Ding Y., Sun Z. Critical role of TCF-1 in repression of the IL-17 gene. PLoS ONE 2011, 6:e24768.
171. MacDonald B.T., Tamai K., He X. Wnt/β-catenin signaling: components, mechanisms, and diseases. Dev Cell 2009, 17:9-26.
172. Lovett-Racke A.E., Hussain R.Z., Northrop S., Choy J., Rocchini A., Matthes L., et al. Peroxisome proliferator-activated receptor α agonists as therapy for autoimmune disease. J Immunol 2004, 172:5790-5798.
173. Diab A., Hussain R.Z., Lovett-Racke A.E., Chavis J.A., Drew P.D., Racke M.K. Ligands for the peroxisome proliferator-activated receptor-γ and the retinoid X receptor exert additive anti-inflammatory effects on experimental autoimmune encephalomyelitis. J Neuroimmunol 2004, 148:116-126.
174. Raikwar H.P., Muthian G., Rajasingh J., Johnson C.N., Bright J.J. PPARγ antagonists reverse the inhibition of neural antigen-specific Th1 response and experimental allergic encephalomyelitis by Ciglitazone and 15-deoxy-Δ 12,14-prostaglandin J2. J Neuroimmunol 2006, 178:76-86.
175. Klotz L., Burgdorf S., Dani I., Saijo K., Flossdorf J., Hucke S., et al. The nuclear receptor PPARγ selectively inhibits Th17 differentiation in a T cell-intrinsic fashion and suppresses CNS autoimmunity. J Exp Med 2009, 206:2079-2089.
176. Kanakasabai S., Walline C.C., Chakraborty S., Bright J.J. PPARδ deficient mice develop elevated Th1/Th17 responses and prolonged experimental autoimmune encephalomyelitis. Brain Res 2011, 1376:101-112.
177. + T cells through PPARγ nuclear receptor activation and protects cardiac allografts. J Surg Res 2012, 173:161-170.
178. + Th cells cytotoxic by activating both perforin- and FasL-pathways. Immunol Lett 2012, 144:5-17.
179. Qui H.Z., Hagymasi A.T., Bandyopadhyay S., St Rose M.C., Ramanarasimhaiah R., Menoret A., et al. CD134 plus CD137 dual costimulation induces Eomesodermin in CD4 T cells to program cytotoxic Th1 differentiation. J Immunol 2011, 187:3555-3564.
180. Gordon S.M., Chaix J., Rupp L.J., Wu J., Madera S., Sun J.C., et al. The transcription factors T-bet and Eomes control key checkpoints of natural killer cell maturation. Immunity 2012, 36:55-67.
181. Endo Y., Iwamura C., Kuwahara M., Suzuki A., Sugaya K., Tumes D.J., et al. Eomesodermin controls interleukin-5 production in memory T helper 2 cells through inhibition of activity of the transcription factor GATA3. Immunity 2011, 35:733-745.
182. + T cells. J Immunol 2011, 186:5749-5757.
183. Oliver J.A., Stolberg V.R., Chensue S.W., King P.D. IL-4 acts as a potent stimulator of IFN-γ expression in CD8+ T cells through STAT6-dependent and independent induction of Eomesodermin and T-bet. Cytokine 2012, 57:191-199.
184. + T cells. J Immunol 2011, 186:4573-4578.
185. Mukherjee S., Lindell D.M., Berlin A.A., Morris S.B., Shanley T.P., Hershenson M.B., et al. IL-17-induced pulmonary pathogenesis during respiratory viral infection and exacerbation of allergic disease. Am J Pathol 2011, 179:248-258.
186. Powell J.D., Delgoffe G.M. The mammalian target of rapamycin: linking T cell differentiation, function, and metabolism. Immunity 2010, 33:301-311.
187. Delgoffe G.M., Pollizzi K.N., Waickman A.T., Heikamp E., Meyers D.J., Horton M.R., et al. The kinase mTOR regulates the differentiation of helper T cells through the selective activation of signaling by mTORC1 and mTORC2. Nat Immunol 2011, 12:295-303.
188. Delgoffe G.M., Powell J.D. Exploring functional in vivo consequences of the selective genetic ablation of mTOR signaling in T helper lymphocytes. Methods Mol Biol 2012, 821:317-327.
189. Gulen M.F., Kang Z., Bulek K., Youzhong W., Kim T.W., Chen Y., et al. The receptor SIGIRR suppresses Th17 cell proliferation via inhibition of the interleukin-1 receptor pathway and mTOR kinase activation. Immunity 2010, 32:54-66.
190. McMahon G., Weir M.R., Li X.C., Mandelbrot D.A. The evolving role of mTOR inhibition in transplantation tolerance. J Am Soc Nephrol 2011, 22:408-415.
191. Ma J., Meng Y., Kwiatkowski D.J., Chen X., Peng H., Sun Q., et al. Mammalian target of rapamycin regulates murine and human cell differentiation through STAT3/p63/Jagged/Notch cascade. J Clin Invest 2010, 120:103-114.
192. Lee K., Gudapati P., Dragovic S., Spencer C., Joyce S., Killeen N., et al. Mammalian target of rapamycin protein complex 2 regulates differentiation of Th1 and Th2 cell subsets via distinct signaling pathways. Immunity 2010, 32:743-753.
193. Saxena A., Raychaudhuri S.K., Raychaudhuri S.P. Interleukin-17-induced proliferation of fibroblast-like synovial cells is mTOR dependent. Arthritis Rheum 2011, 63:1465-1466.
194. Munk R., Ghosh P., Ghosh M.C., Saito T., Xu M., Carter A., et al. Involvement of mTOR in CXCL12 mediated T cell signaling and migration. PLoS ONE 2011, 6:e24667.
195. Chen G., Chen S.M., Wang X., Ding X.F., Ding J., Meng L.H. Inhibition of chemokine (C-X-C motif) ligand 12/chemokine (C-X-C motif) receptor 4 axis (CXCL12/CXCR4)-mediated cell migration by targeting mammalian target of rapamycin (mTOR) pathway in human gastric carcinoma cells. J Biol Chem 2012, 287:12132-12141.
196. Chan S. Targeting the mammalian target of rapamycin (mTOR): a new approach to treating cancer. Br J Cancer 2004, 91:1420-1424.
197. Bestard O., Cassis L., Cruzado J.M., Torras J., Franquesa M., Gil-Vernet S., et al. Costimulatory blockade with mTor inhibition abrogates effector T-cell responses allowing regulatory T-cell survival in renal transplantation. Transpl Int 2011, 24:451-460.
198. Delgoffe G.M., Kole T.P., Zheng Y., Zarek P.E., Matthews K.L., Xiao B., et al. The mTOR kinase differentially regulates effector and regulatory T cell lineage commitment. Immunity 2009, 30:832-844.
199. + T cell memory and tumor immunity. Immunity 2011, 34:541-553.
200. Salmond R.J., Zamoyska R. The influence of mTOR on T helper cell differentiation and dendritic cell function. Eur J Immunol 2011, 41:2137-2141.
201. Simarro M., Giannattasio G., Xing W., Lundequist E.M., Stewart S., Stevens R.L., et al. The translational repressor T-cell intracellular antigen-1 (TIA-1) is a key modulator of Th2 and Th17 responses driving pulmonary inflammation induced by exposure to house dust mite. Immunol Lett 2012, 146:8-14.
202. Damgaard C.K., Lykke-Andersen J. Translational coregulation of 5'TOP mRNAs by TIA-1 and TIAR. Genes Dev 2011, 25:2057-2068.
203. Liao W., Lin J.X., Leonard W.J. IL-2 family cytokines: new insights into the complex roles of IL-2 as a broad regulator of T helper cell differentiation. Curr Opin Immunol 2011, 23:598-604.
204. Laurence A., Tato C.M., Davidson T.S., Kanno Y., Chen Z., Yao Z., et al. Interleukin-2 signaling via STAT5 constrains T helper 17 cell generation. Immunity 2007, 26:371-381.
205. Liao W., Lin J.X., Wang L., Li P., Leonard W.J. Modulation of cytokine receptors by IL-2 broadly regulates differentiation into helper T cell lineages. Nat Immunol 2011, 12:551-559.
206. + T cell population of rheumatoid arthritis patients. Immunol Lett 2010, 127:150-156.
207. Carrier Y., Yuan J., Kuchroo V.K., Weiner H.L. Th3 cells in peripheral tolerance. II. TGF-β-transgenic Th3 cells rescue IL-2-deficient mice from autoimmunity. J Immunol 2007, 178:172-178.
208. Stumhofer J.S., Hunter C.A. Advances in understanding the anti-inflammatory properties of IL-27. Immunol Lett 2008, 117:123-130.
209. Liu H., Rohowsky-Kochan C. Interleukin-27-mediated suppression of human Th17 cells is associated with activation of STAT1 and suppressor of cytokine signaling protein 1. J Interferon Cytokine Res 2011, 31:459-469.
210. + T cells in part through STAT3. Immunol Lett 2011, 138:47-53.
211. Kalliolias G.D., Zhao B., Triantafyllopoulou A., Park-Min K.H., Ivashkiv L.B. Interleukin-27 inhibits human osteoclastogenesis by abrogating RANKL-mediated induction of nuclear factor of activated T cells c1 and suppressing proximal RANK signaling. Arthritis Rheum 2010, 62:402-413.
212. Sasaoka T., Ito M., Yamashita J., Nakajima K., Tanaka I., Narita M., et al. Treatment with IL-27 attenuates experimental colitis through the suppression of the development of IL-17-producing T helper cells. Am J Physiol Gastrointest Liver Physiol 2011, 300:568-576.
213. Toussirot E. The IL23/Th17 pathway as a therapeutic target in chronic inflammatory diseases. Inflamm Allergy Drug Targets 2012, 11:159-168.
214. Stockinger B., Hirota K., Duarte J., Veldhoen M. External influences on the immune system via activation of the aryl hydrocarbon receptor. Semin Immunol 2011, 23:99-105.
215. Ivanov I.I., Atarashi K., Manel N., Brodie E.L., Shima T., Karaoz U., et al. Induction of intestinal Th17 cells by segmented filamentous bacteria. Cell 2009, 139:485-498.
216. Ziolkowska M., Koc A., Luszczykiewicz G., Ksiezopolska-Pietrzak K., Klimczak E., Chwalinska-Sadowska H., et al. High levels of IL-17 in rheumatoid arthritis patients: IL-15 triggers in vitro IL-17 production via cyclosporin A-sensitive mechanism. J Immunol 2000, 164:2832-2838.
217. Raychaudhuri S.P., Raychaudhuri S.K., Genovese M.C. IL-17 receptor and its functional significance in psoriatic arthritis. Mol Cell Biochem 2012, 359:419-429.
218. Freysdottir J., Sigurpalsson M.B., Omarsdottir S., Olafsdottir E.S., Vikingsson A., Hardardottir I. Ethanol extract from birch bark (Betula pubescens) suppresses human dendritic cell mediated Th1 responses and directs it towards a Th17 regulatory response in vitro. Immunol Lett 2011, 136:90-96.
219. + pathogenic T cell in autoimmune arthritis. Immunol Lett 2011, 135:50-58.